Treating Osteoporosis with Denosumab in Patients on Hemodialysis: The Good, the Bad, and the Ugly.
作者信息
Nickolas Thomas L
机构信息
Columbia University Irving Medical Center, New York, New York.
出版信息
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1116-1118. doi: 10.2215/CJN.0000000000000260. Epub 2023 Aug 3.
Abstract
摘要
相似文献
1
Treating Osteoporosis with Denosumab in Patients on Hemodialysis: The Good, the Bad, and the Ugly.在接受血液透析的患者中使用地诺单抗治疗骨质疏松症：利弊与风险
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1116-1118. doi: 10.2215/CJN.0000000000000260. Epub 2023 Aug 3.
2
Bone Histomorphometry in an Osteoporotic Hemodialysis Patient Treated With Denosumab.地诺单抗治疗的骨质疏松血液透析患者的骨组织形态计量学
Ther Apher Dial. 2018 Jun;22(3):302-304. doi: 10.1111/1744-9987.12489. Epub 2017 Jun 8.
3
Impact of Zoledronic Acid on Bone Mineral Density and Trabecular Score Following Denosumab Discontinuation in Older Adults in Long-Term Care.唑来膦酸对长期护理机构中老年人停用地诺单抗后骨密度和骨小梁评分的影响
Calcif Tissue Int. 2025 Mar 27;116(1):55. doi: 10.1007/s00223-025-01364-y.
4
Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation.双膦酸盐、地诺单抗和甲状旁腺激素类似物用于肺移植后骨质疏松症的比较安全性和疗效
Pharmacotherapy. 2025 Jul 3. doi: 10.1002/phar.70040.
5
RANK-ligand inhibition to combat sarcopenia with underlying osteoporosis: a study protocol for a randomized, double-blind, double-dummy, active-controlled trial.通过抑制核因子κB受体活化因子配体治疗伴骨质疏松症的肌少症：一项随机、双盲、双模拟、活性对照试验的研究方案
Trials. 2025 Aug 4;26(1):269. doi: 10.1186/s13063-025-08976-7.
6
Denosumab for dialysis patients with osteoporosis: A cohort study.地舒单抗治疗骨质疏松症透析患者：一项队列研究。
Sci Rep. 2020 Feb 12;10(1):2496. doi: 10.1038/s41598-020-59143-8.
7
Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis.在使用替诺福韦的慢性乙型肝炎骨质疏松患者中，地诺单抗与双膦酸盐类药物骨密度变化的比较。
Osteoporos Int. 2025 Jul 11. doi: 10.1007/s00198-025-07602-1.
8
Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis.地诺单抗在先前接受过其他药物治疗的骨质疏松症患者中的安全性和有效性：一项系统评价和荟萃分析。
Expert Opin Drug Saf. 2018 Apr;17(4):413-428. doi: 10.1080/14740338.2018.1430764. Epub 2018 Jan 25.
9
Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.用于减少早期和局部晚期乳腺癌女性骨丢失的骨修饰剂：一项网络荟萃分析。
Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD013451. doi: 10.1002/14651858.CD013451.pub2.
10
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.患有慢性肾脏病患者使用骨质疏松症药物的利弊：系统评价和荟萃分析。
Ann Intern Med. 2017 May 2;166(9):649-658. doi: 10.7326/M16-2752. Epub 2017 Apr 11.
引用本文的文献
1
The Relationship between Changes in Single-Nucleotide Polymorphism-Associated Metabolites and Elite Athletes' Adaptive Cardiac Function.单核苷酸多态性相关代谢物变化与优秀运动员适应性心脏功能之间的关系
J Cardiovasc Dev Dis. 2023 Sep 18;10(9):400. doi: 10.3390/jcdd10090400.
本文引用的文献
1
Long-Term Effect of Denosumab on Bone Disease in Patients with CKD.地舒单抗治疗慢性肾脏病患者骨病的长期疗效。
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1195-1203. doi: 10.2215/CJN.0000000000000213. Epub 2023 Jun 14.
2
Effects of denosumab on bone mineral density and bone metabolism in patients with end-stage renal disease: A systematic review and meta-analysis.地舒单抗对终末期肾病患者骨密度和骨代谢的影响：系统评价和荟萃分析。
Hemodial Int. 2023 Oct;27(4):352-363. doi: 10.1111/hdi.13098. Epub 2023 Jun 1.
3
Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.依降钙素在各种肾脏疾病中的低钙血症风险：一项基于人群的队列研究。
J Bone Miner Res. 2023 May;38(5):650-658. doi: 10.1002/jbmr.4804. Epub 2023 Apr 9.
4
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project.验证骨密度变化的替代阈值效应作为骨折结局的替代终点：FNIH-ASBMR SABRE 项目。
J Bone Miner Res. 2022 Jan;37(1):29-35. doi: 10.1002/jbmr.4433. Epub 2021 Sep 24.
5
Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis.中重度慢性肾脏病患者口服双膦酸盐类药物的安全性：一项跨国队列分析。
J Bone Miner Res. 2021 May;36(5):820-832. doi: 10.1002/jbmr.4235. Epub 2021 Feb 8.
6
Management of Osteoporosis in CKD.慢性肾脏病患者的骨质疏松症管理。
Clin J Am Soc Nephrol. 2018 Jun 7;13(6):962-969. doi: 10.2215/CJN.11031017. Epub 2018 Feb 27.
7
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.地舒单抗停药后发生的椎体骨折：一项 FREEDOM 随机安慰剂对照试验及其延伸的事后分析。
J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22.
8
Hip fractures and the contribution of cortical versus trabecular bone to femoral neck strength.髋部骨折以及皮质骨与小梁骨对股骨颈强度的贡献。
J Bone Miner Res. 2009 Mar;24(3):468-74. doi: 10.1359/jbmr.081108.
9
Relationship between age, renal function and bone mineral density in the US population.美国人群中年龄、肾功能与骨密度之间的关系。
Osteoporos Int. 2003 Jul;14(7):570-6. doi: 10.1007/s00198-003-1435-y. Epub 2003 Jul 3.
10
A structural approach to renal bone disease.一种针对肾性骨病的结构性方法。
J Bone Miner Res. 1998 Aug;13(8):1213-20. doi: 10.1359/jbmr.1998.13.8.1213.
Zotero 插件